BTK and B-cell chronic lymphocytic leukemia: CLL treatment has evolved from chemoimmunotherapy to small-molecule-based precision therapies like BTK inhibitors (ibrutinib and others) and BCL-2 inhibitors (venetoclax) that significantly improve patient outcomes, with CAR-T cells and other new therapeutics as emerging options [4,7,8].